<DOC>
	<DOCNO>NCT01448486</DOCNO>
	<brief_summary>HIV relate cognitive impairment still occur despite highly active antiretroviral therapy ( HAART ) . HIV disease affect brain 20-40 % patient advance HIV disease lead vary degree cognitive impairment , recently term HIV associate neurocognitive disorder ( HAND ) . HAND may occur patient virally suppress blood CSF . Patients HIV Associated Neurological Disorders ( HAND ) virally suppress blood cerebrospinal fluid ( CSF ) , whilst highly active antiretroviral therapy ( HAART ) regimen may significant cognitive improvement HAART intensification medication RaltegravirÍ¾ compare remain exist regimen . This study prospective , interventional , randomise unblinded control clinical trial . The aim study determine whether HAART intensification medication Raltegravir , lead significant improvement HIV associate neurological disorder ( HAND ) . Patients recent progression ( within 6 month ) HAND ( validated neuropsychological assessment ) HAART virally suppress ( &lt; 50 copy per ml ) blood CSF randomise exist HAART regimen intensify raltegravir 400mg twice daily , . The control arm remain medication regimen prescribe . The target enrol 110 patient control group , 110 patient Raltegravir intensification group . Patients undergo baseline neuropsychological testing , MRI , blood test , cerebral spinal fluid ( CSF ) test ( via lumbar puncture ) . The method use determine effectiveness add Raltegravir , include neuropsychological test 6 month ; neuropsychological testing , MRI CSF assessment 12 month . Neuropsychological testing complete 6 12 month complete `` blind assessor '' , knowledge arm ( treatment control ) participant enrol . An evaluation ( neuropsychological testing ) perform patient deteriorate course study , recognise patient 's managing physician . The decision Antiretroviral medication regimen use case determine manage physician . At end study protocol ( 12 month ) patient 's HAART therapy manage primary physician .</brief_summary>
	<brief_title>A Study Neurological Effects Adding Raltegravir HAART Regimen Patients With HIV</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Neurocognitive Disorders</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV positive On HAART , plasma HIV viral load &lt; 50 copies/ml previous 12 month Able provide inform consent HAND diagnosis , symptom progression within previous 6 month ( exist HAART regimen ) NonHIV related neurological disorder active CNS opportunistic infection ( assess full blood count , electrolytes , creatinine , glucose , LFT 's , cryptococcal antigen , VDRL , MRI brain scan CSF fluid analysis cell count , protein , glucose , culture , VDRL cryptococcal antigen ) Psychiatric disorder psychotic axis Current major depression Current substance use disorder , severe substance use disorder within 12 month study entry Active HCV ( detectable HCV RNA ) History loss consciousness &gt; 1 hour Nonproficient English Medications know pharmacologically interact ARV 's Currently take Integrase Inhibitor Pregnancy ( assessed urine pregnancy test )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HAND</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>HIV Associated Neurocognitive Disorders</keyword>
	<keyword>Neuro-HAART</keyword>
	<keyword>Neurocognitive</keyword>
	<keyword>Neurology</keyword>
</DOC>